Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT SOLUTAB versus DEXLANSOPRAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT SOLUTAB versus DEXLANSOPRAZOLE.
DEXILANT SOLUTAB vs DEXLANSOPRAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.
30 mg orally once daily for 4-8 weeks; for non-erosive GERD, 30 mg orally once daily for 4 weeks; for erosive esophagitis, 60 mg orally once daily for up to 8 weeks; for maintenance of healed EE and relief of heartburn, 30 mg orally once daily. Administer without regard to food; dissolve tablet in water.
30 mg orally once daily for 4 weeks for healing of erosive esophagitis; maintenance therapy: 30 mg orally once daily for up to 6 months. For GERD: 30 mg orally once daily for 4 weeks.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Technetium Tc-99m medronate
"The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateTerminal elimination half-life is approximately 1-2 hours; however, the pharmacodynamic half-life (duration of acid suppression) is prolonged due to accumulation in parietal cell canaliculi.
1-2 hours; clinical context: duration of acid suppression exceeds half-life due to binding to proton pumps
Renal (approx. 53% as metabolites, <2% as unchanged drug), biliary/fecal (approx. 47%).
Renal: 0% unchanged; metabolites eliminated via urine (51%) and feces (48%)
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor
Dexlansoprazole + Pamidronic acid
"The therapeutic efficacy of Pamidronic acid can be decreased when used in combination with Dexlansoprazole."